title: Strategies for designing and validating immunostimulatory siRNAs.
abstract: Specific clinical applications of RNA interference (RNAi) can benefit from a concurrent activation of the immune system. This is the case for small interfering RNAs (siRNAs) with antitumor or antiviral activities. This chapter provides a brief overview of the strategies reported to date to design siRNAs with gene silencing and immune activating properties, as well as methods for the validation of immunostimulatory activities.
authors.affiliation: Monash Institute of Medical Research, Monash University, Clayton, VIC, Australia. michael.gantier@monash.edu
authors.forename: Michael P
authors.initials: MP
authors.lastname: Gantier
mesh_terms: D000276:Adjuvants, Immunologic / Q000235:genetics*; D001483:Base Sequence; D002460:Cell Line; D016207:Cytokines / Q000096:biosynthesis; D020868:Gene Silencing; D005818:Genetic Engineering / Q000379:methods*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics*; D051199:Toll-Like Receptor 7 / Q000378:metabolism; D051217:Toll-Like Receptor 9 / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D034741:RNA, Small Interfering; C495348:TLR7 protein, human; D051199:Toll-Like Receptor 7; D051217:Toll-Like Receptor 9